Unlock instant, AI-driven research and patent intelligence for your innovation.

A Short Peptide Inhibitor Inhibiting the Aggregation of Amylin

A technology of amyloid peptide and inhibitor, which is applied in the field of biological preparations, can solve the problems of rare species, low inhibition rate, and large molecular weight, and achieve the effects of convenient drug use, reduced toxicity, and small molecular weight

Active Publication Date: 2019-12-31
辽宁纽帕特生物科技有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The object of the present invention is to provide a short peptide inhibitor that inhibits the aggregation of islet amyloid polypeptide (IAPP), in order to solve the problems of existing inhibitors such as rare types, large molecular weight, low inhibition rate and high cost. A short peptide inhibitor of proline that prevents the aggregation of IAPP to form a β-sheet, has a smaller molecular weight, good hydrophobicity, good stability, and is easy to bind to IAPP, which can effectively inhibit the aggregation of IAPP, thereby protecting the function of islets of pancreas. It has broad application prospects in the medicine of its complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A Short Peptide Inhibitor Inhibiting the Aggregation of Amylin
  • A Short Peptide Inhibitor Inhibiting the Aggregation of Amylin
  • A Short Peptide Inhibitor Inhibiting the Aggregation of Amylin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Effects of Different Concentrations of Inhibitors on the Aggregation of IAPP Cultured in Vitro

[0031] (1) Reagent preparation

[0032] Take out the IAPP, ANFLVH and the short peptide inhibitor FLPNF of the present invention stored in the refrigerator at -80°C and place them at room temperature. Among them, ANFLVH and the short peptide inhibitor FLPNF of the present invention are synthesized by entrusting a biological company, lyophilized at 1 mg / tube pink.

[0033] A ThS solution with a concentration of 0.5wt.% was prepared with deionized water for later use.

[0034] IAPP was dissolved in the above-mentioned 0.5 wt.% ThS solution to make the IAPP concentration 40umol / L, and the IAPP solution was prepared.

[0035] Dissolve ANFLVH in the above ThS solution, prepare ANFLVH concentrations of 300umol / L, 400umol / L and 500umol / L, respectively, and prepare ANFLVH solutions.

[0036] FLPNF was dissolved in the above ThS solution so that the concentrations of FLP...

Embodiment 2

[0039] Example 2 Effects of Inhibitors on the Aggregation of IAPP in INS1 (Rat Insulinoma) Cells (hIAPP-INS1) Transfected with Human IAPP

[0040] Take a 96-well plate and dilute INS1 (rat insulinoma cells) with culture medium to a density of 5×10 according to the conventional cell culture method. 4 cells / mL, cells were plated, and a blank control group, a positive control group, and an experimental group were set up in three groups, and 30 wells were selected in the middle area, with 10 wells in each group and 100 μL in each well, that is, 5000 cells / well, and placed in a 37°C, 5%CO 2 After the cell incubator was adhered to the wall, the medium was changed, and the human IAPP gene transfection test was carried out according to the conventional cell transfection method to form INS1 cells transfected with human IAPP, namely the test cell hIAPP-INS1.

[0041] After successful transfection, the blank control group was added with 100 μL of culture fluid, the positive control grou...

Embodiment 3

[0043] Example 3 Effects of Different Concentrations of Inhibitors on the Aggregation of IAPP in INS1 (Rat Insulinoma) Cells (hIAPP-INS1) Transfected with Human IAPP

[0044] Take the 96-well plate, according to the conventional cell culture method, the rat insulinoma cell INS1 was dispersed and diluted with the culture medium to a western density of 5×10 4 cells / mL, add 5,000 cells to each well of the 60 wells in the middle, and put them in 37°C, 5% CO 2 After the cell incubator was adhered to the wall, the medium was changed and the human IAPP gene transfection test was carried out according to the conventional cell transfection method to obtain cells for the hIAPP-INS1 test.

[0045] After successful transfection, co-culture experiments with different concentrations of short peptide inhibitors and cells were carried out, and 5 experimental groups with different concentration gradients were set up. At the same time, a blank control group cultured in ordinary culture medium ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
hydrophobicityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an oligopeptide inhibitor for inhibiting aggregation of islet amyloid polypeptide, and belongs to the technical field of biologicals. According to the adopted technical scheme, the oligopeptide inhibitor for inhibiting the aggregation of the islet amyloid polypeptide is provided, and an amino acid sequence of the oligopeptide inhibitor is FLPNF; and a pharmaceutic preparation for preventing and treating diabetes and complications of the diabetes based on the oligopeptide inhibitor FLPNF is further provided. The oligopeptide inhibitor provided by the invention is small in molecular weight, good in effect, capable of effectively inhibiting IAPP (islet amyloid polypeptide) aggregation and reducing islet cytotoxicity caused by IAPP aggregation, and wide in application prospect; and the oligopeptide inhibitor is convenient to dose, suitable for application to the public, easy and convenient to synthesize, low in cost, and widely suitable for industrialization production.

Description

technical field [0001] The invention relates to the technical field of biological preparations, in particular to a short peptide inhibitor for inhibiting aggregation of amylin-like polypeptide. Background technique [0002] Diabetes is a syndrome of glucose, protein and lipid metabolism disorders caused by insufficient insulin or defects in insulin cell metabolism. It is divided into type I diabetes and type II diabetes, and the number of type II diabetes accounts for the total number of diabetic patients 85-90%, and it is also easy to cause complications such as diabetic nephropathy and high blood pressure, seriously threatening the health and life of patients. [0003] Clinical pathology found that 90% of type 2 diabetic patients had islet amyloid deposition in the islets, and amyloid deposition also occurred rapidly inside and outside the cells after islet transplantation, resulting in a high necrosis rate of transplanted islets. The study found that one of the main reas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K38/08A61P3/10
CPCA61K38/00C07K7/06
Inventor 张佳林石悦吕武焦奥李晓航张城硕孙宁
Owner 辽宁纽帕特生物科技有限公司